{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:53:35Z","timestamp":1791852815764,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Disparities in up-to-date cervical cancer screening rates persist among women, including those identifying as lesbian, gay, bisexual or other sexual orientation (LGB+), highlighting the need for more inclusive and targeted screening interventions. With human papillomavirus at-home self-testing recently approved, we studied cervical cancer screening preferences by sexual orientation among persons assigned female at birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined cervical cancer screening preferences among a nationally representative sample of persons assigned female at birth aged 25\u201365 years in the 2024 Health Information National Trends Survey who did not self-report a history of cervical cancer. We assessed variation in preference for at-home self-testing or clinician-delivered cervical cancer screening by sexual orientation using weighted Rao-Scott chi-square tests and multivariate multinomial regression. We also examined reasons for preferring at-home self-testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analytical sample included 2,168 respondents. Most self-identified as heterosexual (88.43%) and preferred cervical cancer screening by clinicians (61.45%). Cervical cancer screening preferences differed by sexual orientation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). LGB+ versus heterosexual respondents more frequently preferred at-home self-testing (30.97% versus 19.53%), whereas heterosexual respondents more frequently preferred testing by clinician than their LGB+ counterparts (62.81% versus 50.38%). The odds of preferring at-home self-testing over clinician-delivered screening were higher among LGB+ versus heterosexual respondents (adjusted odds ratio\u2009=\u20092.04, 95% confidence interval\u2009=\u20091.17\u02d73.53), after adjusting for age, household annual income, marital status, health care utilization, race\/ethnicity, and health insurance. The most frequently endorsed reason for preferring at-home self-testing was privacy (66.25%). Preferring at-home self-testing due to not taking time off work (35.22%), saving transportation cost (34.24%), and avoiding embarrassment (39.41%) were endorsed less frequently. Reasons for preferring at-home self-testing did not differ by sexual orientation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LGB+ respondents more frequently preferred at-home self-testing compared to heterosexual respondents. These findings highlight the potential utility of at-home self-testing in addressing screening preferences and barriers among LGB+ persons.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-026-04678-7","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:53:48Z","timestamp":1784274828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cervical cancer screening preferences by sexual orientation among persons assigned female at birth"],"prefix":"10.1186","volume":"26","author":[{"given":"Wei Yi","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"St. Sauver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy L.","family":"MacLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila J.","family":"Finney Rutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"4678_CR1","unstructured":"National Cancer Institute. Cervical cancer screening. 2025. Available from: https:\/\/progressreport.cancer.gov\/detection\/cervical_cancer. Accessed 29 May 2025."},{"key":"4678_CR2","unstructured":"Office of Disease Prevention and Health Promotion. Increase the proportion of females who get screened for cervical cancer \u2014 C\u201309. Available from: https:\/\/health.gov\/healthypeople\/objectives-and-data\/browse-objectives\/cancer\/increase-proportion-females-who-get-screened-cervical-cancer-c-09\/data. Accessed 29 May 2025."},{"issue":"5","key":"4678_CR3","doi-asserted-by":"publisher","first-page":"e248886","DOI":"10.1001\/jamanetworkopen.2024.8886","volume":"7","author":"K Baumann","year":"2024","unstructured":"Baumann K, Matzke H, Peterson CE, Geller S, Flores R, Prachand NG, et al. Sexual orientation and cervical cancer screening among cisgender women. JAMA Netw Open. 2024;7(5):e248886.","journal-title":"JAMA Netw Open"},{"key":"4678_CR4","doi-asserted-by":"publisher","first-page":"108223","DOI":"10.1016\/j.ypmed.2025.108223","volume":"191","author":"K Baumann","year":"2025","unstructured":"Baumann K, Peterson CE, Geller S, Awadalla S, Holt HK. U.S. national trends in cervical cancer screening by sexual orientation and race\/ethnicity in cisgender women. Prev Med. 2025;191:108223.","journal-title":"Prev Med"},{"issue":"1","key":"4678_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10552-023-01771-2","volume":"35","author":"E Lin","year":"2024","unstructured":"Lin E, Sleboda P, Rimel BJ, Chen JT, Hernandez DV, Datta GD. Sexual orientation and gender identity inequities in cervical cancer screening by race and ethnicity. Cancer Causes Control. 2024;35(1):133\u201351.","journal-title":"Cancer Causes Control"},{"key":"4678_CR6","doi-asserted-by":"publisher","first-page":"108262","DOI":"10.1016\/j.ypmed.2025.108262","volume":"194","author":"JC Spencer","year":"2025","unstructured":"Spencer JC, Zhang H, Charlton BM, Schnarrs PW, Kuehne F, Siebert U, et al. Cervical cancer screening and risk factor prevalence by sexual identity: A comparison across three national surveys in the United States. Prev Med. 2025;194:108262.","journal-title":"Prev Med"},{"issue":"1","key":"4678_CR7","doi-asserted-by":"publisher","first-page":"e2143582","DOI":"10.1001\/jamanetworkopen.2021.43582","volume":"5","author":"R Suk","year":"2022","unstructured":"Suk R, Hong YR, Rajan SS, Xie Z, Zhu Y, Spencer JC. Assessment of US Preventive Services Task Force guideline-concordant cervical cancer screening rates and reasons for underscreening by age, race and ethnicity, sexual orientation, rurality, and insurance, 2005 to 2019. JAMA Netw Open. 2022;5(1):e2143582.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"4678_CR8","doi-asserted-by":"publisher","first-page":"e250392","DOI":"10.1001\/jamanetworkopen.2025.0392","volume":"8","author":"EL Akre","year":"2025","unstructured":"Akre EL, Yang CW, Bauer GR, Mackwood MB, O\u2019Malley AJ, Fisher ES, et al. Sexual orientation- and gender identity-affirming activities provided in primary care. JAMA Netw Open. 2025;8(3):e250392.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"4678_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/lgbt.2023.0224","volume":"11","author":"S Lamba","year":"2024","unstructured":"Lamba S, Jones KT, Grozdanic T, Moy E. Differences by sexual orientation in patient-centered care outcomes for veterans utilizing primary care services at the Veterans Health Administration. LGBT Health. 2024;11(6):455\u201364.","journal-title":"LGBT Health"},{"issue":"12","key":"4678_CR10","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/13691058.2023.2176548","volume":"25","author":"J Campbell","year":"2023","unstructured":"Campbell J, Nathoo A, Chard S, Messenger D, Walker M, Bartels SA. Lesbian, gay, bisexual, transgender and or queer patient experiences in Canadian primary care and emergency departments: A literature review. Cult Health Sex. 2023;25(12):1707\u201324.","journal-title":"Cult Health Sex"},{"key":"4678_CR11","unstructured":"US Food & Drug Administration, Roundup FDA. May 17, 2024. 2024. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-roundup-may-17-2024#:~:text=On%20Thursday%2C%20the%20FDA%20granted,or%20after%20platinum%2Dbased%20chemotherapy. Accessed 11 Sep 2025."},{"issue":"5","key":"4678_CR12","doi-asserted-by":"publisher","first-page":"e2511081","DOI":"10.1001\/jamanetworkopen.2025.11081","volume":"8","author":"MB Fitzpatrick","year":"2025","unstructured":"Fitzpatrick MB, Behrens CM, Hibler K, Parsons C, Kaplan C, Orso R, et al. Clinical validation of a vaginal cervical cancer screening self-collection method for at-home use: A nonrandomized clinical trial. JAMA Netw Open. 2025;8(5):e2511081.","journal-title":"JAMA Netw Open"},{"key":"4678_CR13","unstructured":"Waters Corporation. Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay. 2026. Available from: https:\/\/ir.waters.com\/News--Events\/newsroom\/news-details\/2026\/Waters-Announces-FDA-Clearance-of-the-Most-Comprehensive-At-Home-Cervical-Cancer-Screening-Tool-the-Onclarity-HPV-Self-Collection-Kit-and-FDA-Approved-HPV-Assay\/default.aspx. Accessed 14 May 2026."},{"issue":"1","key":"4678_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10552-023-01778-9","volume":"35","author":"A Garg","year":"2024","unstructured":"Garg A, Galvin AM, Griner SB, Rosberger Z, Daley EM, Thompson EL. HPV self-sampling among women in the United States: Preferences for implementation. Cancer Causes Control. 2024;35(1):167\u201376.","journal-title":"Cancer Causes Control"},{"issue":"5","key":"4678_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jogn.2023.05.114","volume":"52","author":"E Liebermann","year":"2023","unstructured":"Liebermann E, Fontenot HB, Lim E, Matsunaga M, Zimet G, Allen JD. Preferred location for human papillomavirus self-sampling for cervical cancer screening. J Obstet Gynecol Neonatal Nurs. 2023;52(5):364\u201373.","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"issue":"4","key":"4678_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/09691413241260019","volume":"31","author":"KL MacLaughlin","year":"2024","unstructured":"MacLaughlin KL, Jenkins GD, St Sauver J, Fan C, Miller NE, Meyer AF, et al. Primary human papillomavirus testing by clinician- versus self-collection: Awareness and acceptance among cervical cancer screening-eligible women. J Med Screen. 2024;31(4):223\u201331.","journal-title":"J Med Screen"},{"issue":"9","key":"4678_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1001\/jamainternmed.2025.2971","volume":"185","author":"JR Montealegre","year":"2025","unstructured":"Montealegre JR, Hilsenbeck SG, Bulsara S, Parker SL, Amboree TL, Anderson ML, et al. Self-collection for cervical cancer screening in a safety-net setting: The PRESTIS randomized clinical trial. JAMA Intern Med. 2025;185(9):1119\u201327.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"4678_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.amepre.2023.10.020","volume":"66","author":"SL Parker","year":"2024","unstructured":"Parker SL, Amboree TL, Bulsara S, Daheri M, Anderson ML, Hilsenbeck SG, et al. Self-sampling for human papillomavirus testing: Acceptability in a U.S. safety net health system. Am J Prev Med. 2024;66(3):540\u20137.","journal-title":"Am J Prev Med"},{"issue":"11","key":"4678_CR19","doi-asserted-by":"publisher","first-page":"e1914729","DOI":"10.1001\/jamanetworkopen.2019.14729","volume":"2","author":"RL Winer","year":"2019","unstructured":"Winer RL, Lin J, Tiro JA, Miglioretti DL, Beatty T, Gao H, et al. Effect of mailed human papillomavirus test kits vs usual care reminders on cervical cancer screening uptake, precancer detection, and treatment: A randomized clinical trial. JAMA Netw Open. 2019;2(11):e1914729.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"4678_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/OLQ.0000000000000944","volume":"46","author":"PL Reiter","year":"2019","unstructured":"Reiter PL, Shoben AB, McDonough D, Ruffin MT, Steinau M, Unger ER, et al. Results of a pilot study of a mail-based human papillomavirus self-testing program for underscreened women from Appalachian Ohio. Sex Transm Dis. 2019;46(3):185\u201390.","journal-title":"Sex Transm Dis"},{"issue":"4","key":"4678_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/jfprhc-2014-101004","volume":"41","author":"PL Reiter","year":"2015","unstructured":"Reiter PL, McRee AL. Cervical cancer screening (Pap testing) behaviours and acceptability of human papillomavirus self-testing among lesbian and bisexual women aged 21\u201326 years in the USA. J Fam Plann Reprod Health Care. 2015;41(4):259\u201364.","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"2","key":"4678_CR22","doi-asserted-by":"publisher","first-page":"e2558841","DOI":"10.1001\/jamanetworkopen.2025.58841","volume":"9","author":"J Fokom Domgue","year":"2026","unstructured":"Fokom Domgue J, Chandra M, Oladoyin O, Desai M, Yu R, Shete S. Women\u2019s preferences for home-based self-sampling or clinic-based testing for cervical cancer screening. JAMA Netw Open. 2026;9(2):e2558841.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"4678_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/AOG.0000000000006147","volume":"147","author":"J Qin","year":"2026","unstructured":"Qin J, Martinez G, Holt HK, Gopalani SV, Trivers KF, Miller JW, et al. Preferences among U.S. women for cervical cancer screening with self-collected specimens for human papillomavirus testing. Obstet Gynecol. 2026;147(3):306\u201312.","journal-title":"Obstet Gynecol"},{"key":"4678_CR24","unstructured":"National Cancer Institute. Health Information National Trends Survey 7 (HINTS 7): HINTS 7 Methodology Report. Bethesda MD. 2025. Available from: https:\/\/hints.cancer.gov\/docs\/methodologyreports\/HINTS_7_MethodologyReport.pdf."},{"issue":"5","key":"4678_CR25","first-page":"321","volume":"70","author":"ETH Fontham","year":"2020","unstructured":"Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321\u201346.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4678_CR26","first-page":"e70041","volume":"76","author":"RB Perkins","year":"2026","unstructured":"Perkins RB, Wolf AMD, Church TR, Elkin EB, Skates SJ, Etzioni RD, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;76(1):e70041.","journal-title":"CA Cancer J Clin"},{"key":"4678_CR27","unstructured":"National Cancer Institute. Survey Instruments. Bethesda MD. 2025. Available from: https:\/\/hints.cancer.gov\/data\/survey-instruments.aspx#H7SurvMat. Accessed 4 Nov 2025."}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-026-04678-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04678-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04678-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:43:53Z","timestamp":1791852233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-026-04678-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4678"],"URL":"https:\/\/doi.org\/10.1186\/s12905-026-04678-7","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data collection for HINTS 7 was reviewed and approved by the Westat Institutional Review Board. While the Declaration of Helsinki was not formally adopted within the US regulatory framework, the HINTS 7 survey was conducted in accordance with applicable U.S. federal regulations governing research involving human participants with ethical oversight provided in accordance with the U.S. Common Rule (45 CFR 46). HINTS 7 survey participants provided informed consent at the time of administration. Our study is a secondary analysis of publicly available, de-identified data, which does not constitute human subjects research; therefore, no additional ethical approval or consent was required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. MacLaughlin currently serves as a member of the steering committee for the American Cancer Society\u2019s National Roundtable on Cervical Cancer and as a co-chair of the HPV Self-Collection work group for the American Cancer Society\u2019s National Roundtable on Cervical Cancer. All other authors have no potential conflicts of interest to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"514"}}